The endocrine disease treatment developer pushed its overall funding past $160m in a round featuring Novo, Sham and Mass General Brigham.

Amolyt Pharma, a France-based developer of treatments for endocrine diseases, completed an $80m series B round yesterday that included pharmaceutical firm Novo, hospital operator Mass General Brigham and insurance firm Sham.

Sectoral Asset Management and Andera Partners co-led the round, which also featured Atem Capital, Kurma Partners, LSP, Bpifrance’s Innobio 2 vehicle, Orbimed, Eurazeo, Pontifax and Credit Agricole Creation.

Novo, Mass General Brigham and Sham invested through Novo Ventures, Mass General Brigham Ventures and Sham Innovation Santé/Turenne Capital respectively.

Amolyt…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn